Moreover, additional proteins can contribute to ICD in CRC, as demonstrated by treatment with a novel topoisomerase inhibitor that induces the release of Annexin A1 (ANXA1), as well as HMGB1 and calreticulin (Fig. 1, red panel) [114]. This evidence concerns the gene HMGB1 and colorectal carcinoma.